executive deferred compensation plan for the company 2019s executives and members of the board of directors , the company adopted the illumina , inc . deferred compensation plan ( the plan ) that became effective january 1 , 2008 . eligible participants can contribute up to 80% ( 80 % ) of their base salary and 100% ( 100 % ) of all other forms of compensation into the plan , including bonus , commission and director fees . the company has agreed to credit the participants 2019 contributions with earnings that reflect the performance of certain independent investment funds . on a discretionary basis , the company may also make employer contributions to participant accounts in any amount determined by the company . the vesting schedules of employer contributions are at the sole discretion of the compensation committee . however , all employer contributions shall become 100% ( 100 % ) vested upon the occurrence of the participant 2019s disability , death or retirement or a change in control of the company . the benefits under this plan are unsecured . participants are generally eligible to receive payment of their vested benefit at the end of their elected deferral period or after termination of their employment with the company for any reason or at a later date to comply with the restrictions of section 409a . as of december 28 , 2008 , no employer contributions were made to the plan . in january 2008 , the company also established a rabbi trust for the benefit of its directors and executives under the plan . in accordance with fasb interpretation ( fin ) no . 46 , consolidation of variable interest entities , an interpretation of arb no . 51 , and eitf 97-14 , accounting for deferred compensation arrangements where amounts earned are held in a rabbi trust and invested , the company has included the assets of the rabbi trust in its consolidated balance sheet since the trust 2019s inception . as of december 28 , 2008 , the assets of the trust and liabilities of the company were $ 1.3 million . the assets and liabilities are classified as other assets and accrued liabilities , respectively , on the company 2019s balance sheet as of december 28 , 2008 . changes in the values of the assets held by the rabbi trust accrue to the company . 14 . segment information , geographic data and significant customers during the first quarter of 2008 , the company reorganized its operating structure into a newly created life sciences business unit , which includes all products and services related to the research market , namely the beadarray , beadxpress and sequencing product lines . the company also created a diagnostics business unit to focus on the emerging opportunity in molecular diagnostics . for the year ended december 28 , 2008 , the company had limited activity related to the diagnostics business unit , and operating results were reported on an aggregate basis to the chief operating decision maker of the company , the chief executive officer . in accordance with sfas no . 131 , disclosures about segments of an enterprise and related information , the company operated in one reportable segment for the year ended december 28 , 2008 . the company had revenue in the following regions for the years ended december 28 , 2008 , december 30 , 2007 and december 31 , 2006 ( in thousands ) : year ended december 28 , year ended december 30 , year ended december 31 .
for the year ended december 28 , 2008 what was the ratio of the united states to the united kingdom revenues
net revenues are attributable to geographic areas based on the region of destination . illumina , inc . notes to consolidated financial statements 2014 ( continued ) .